Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2
9 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3
9 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2
9 December 2025
··
B2Gold Corp (BTG) Stock Update for December 9, 2025: Goose Mine Milestone, Q3 Beat and Analyst Price Targets

B2Gold Corp (BTG) Stock Update for December 9, 2025: Goose Mine Milestone, Q3 Beat and Analyst Price Targets

B2Gold Corp is back in the spotlight after achieving commercial production at its new Goose Mine in Nunavut, delivering a strong third quarter, and drawing a mix of upgrades and downgrades from Wall Street. At the same time, the macro backdrop is unusually favorable: spot gold is trading around $4,200 per ounce, near record highs, as investors brace for the next Federal Reserve moves. Reuters+1
9 December 2025
····
Playboy, Inc. (PLBY) Stock in 2025: First Profit, Licensing Pivot and High‑Risk Upside – What Investors Need to Know Now

Playboy, Inc. (PLBY) Stock in 2025: First Profit, Licensing Pivot and High‑Risk Upside – What Investors Need to Know Now

Playboy, Inc. has quietly turned into one of the more polarizing small‑cap stories on the market. The iconic brand has posted its first quarterly profit since going public, pushed through a radical shift to an “asset‑light” licensing model, won an $81 million arbitration award, and staged a sharp year‑to‑date rally in its share price. At the same time, it still carries heavy leverage, negative free cash flow and a balance sheet that screens as distressed on several metrics.StockInvest+1
9 December 2025
·
Magnum Ice Cream Company N.V. (MICC) Stock: Fresh Analyst Ratings, Outlook and Risks After the Unilever Demerger – 9 December 2025

Magnum Ice Cream Company N.V. (MICC) Stock: Fresh Analyst Ratings, Outlook and Risks After the Unilever Demerger – 9 December 2025

The Magnum Ice Cream Company N.V. is barely into its first full week as an independently listed company, and the market is already trying to figure out what this €7.8–7.9 billion ice cream giant is really worth. Spun out of Unilever and now trading in Amsterdam, London and New York, Magnum combines some of the world’s best-known ice cream brands with a set of very modern headaches: GLP‑1 weight‑loss drugs, sugar regulation, and big separation costs. Reuters+1
9 December 2025
·
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again in pre‑market action on Tuesday, with quotes between $1.76 and $1.81, pushing its market value to roughly $37–38 million.Benzinga
9 December 2025
·
AlphaTime Acquisition Corp (ATMC) Skyrockets After HCYC Merger Vote: Latest News, Deal Terms and 2026 Outlook

AlphaTime Acquisition Corp (ATMC) Skyrockets After HCYC Merger Vote: Latest News, Deal Terms and 2026 Outlook

As of the morning of December 9, 2025, ATMC was flagged among the top pre‑market gainers, with shares changing hands around $104.70, up roughly 602% from the prior close. RTTNews+1 The move comes just days after shareholders approved a complex merger with Hong Kong insurance broker HCYC and after the Form F‑4 registration statement for the deal became effective.
9 December 2025
··
1 … 522 523 524 525 526 … 608

Google Preferred Source

Follow on Google News
Add as preferred source Open in Google News

Stock Market Today

  • China Gold Imports Jump 89% in H1 2026 as Prices Slide
    July 29, 2026, 5:47 AM EDT. China's gold imports surged 89.1% year-on-year to 864.95 tons in the first half of 2026, spurred by declining global prices, a firmer yuan, and ongoing demand. Imports in June stood at 173.34 tons, the highest level recorded since March 2024. Global gold prices registered an 8% decrease and yuan-denominated prices slid 10% over H1, encouraging increased bullion buying among both banks and investors, with exchange-traded funds seeing notable inflows totaling 29 tons.